Enzymatica Publ (Sweden) Performance
| ENZY Stock | SEK 1.46 0.02 1.35% |
The firm shows a Beta (market volatility) of 0.41, which means possible diversification benefits within a given portfolio. As returns on the market increase, Enzymatica Publ's returns are expected to increase less than the market. However, during the bear market, the loss of holding Enzymatica Publ is expected to be smaller as well. At this point, Enzymatica publ AB has a negative expected return of -0.29%. Please make sure to confirm Enzymatica Publ's skewness, rate of daily change, period momentum indicator, as well as the relationship between the accumulation distribution and day typical price , to decide if Enzymatica publ AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enzymatica publ AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 24 M | |
| Total Cashflows From Investing Activities | -6.1 M |
Enzymatica |
Enzymatica Publ Relative Risk vs. Return Landscape
If you would invest 179.00 in Enzymatica publ AB on November 8, 2024 and sell it today you would lose (33.00) from holding Enzymatica publ AB or give up 18.44% of portfolio value over 90 days. Enzymatica publ AB is generating negative expected returns and assumes 3.3873% volatility on return distribution over the 90 days horizon. Simply put, 30% of stocks are less volatile than Enzymatica, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Enzymatica Publ Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enzymatica Publ's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enzymatica publ AB, and traders can use it to determine the average amount a Enzymatica Publ's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0852
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENZY |
Estimated Market Risk
| 3.39 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enzymatica Publ is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enzymatica Publ by adding Enzymatica Publ to a well-diversified portfolio.
Enzymatica Publ Fundamentals Growth
Enzymatica Stock prices reflect investors' perceptions of the future prospects and financial health of Enzymatica Publ, and Enzymatica Publ fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enzymatica Stock performance.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.12) % | |||
| Operating Margin | (1.12) % | |||
| Current Valuation | 613.36 M | |||
| Shares Outstanding | 164.26 M | |||
| Price To Earning | (6.00) X | |||
| Price To Book | 47.25 X | |||
| Price To Sales | 14.29 X | |||
| Revenue | 57.24 M | |||
| EBITDA | (38.19 M) | |||
| Cash And Equivalents | 64.82 M | |||
| Cash Per Share | 0.44 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 0.91 X | |||
| Cash Flow From Operations | (35.87 M) | |||
| Earnings Per Share | (0.37) X | |||
| Total Asset | 157.04 M | |||
| Current Asset | 81 M | |||
| Current Liabilities | 17 M | |||
About Enzymatica Publ Performance
Assessing Enzymatica Publ's fundamental ratios provides investors with valuable insights into Enzymatica Publ's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Enzymatica Publ is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden. Enzymatica operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 24 people.Things to note about Enzymatica publ AB performance evaluation
Checking the ongoing alerts about Enzymatica Publ for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enzymatica publ AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enzymatica publ AB generated a negative expected return over the last 90 days | |
| Enzymatica publ AB may become a speculative penny stock | |
| Enzymatica publ AB has high historical volatility and very poor performance | |
| The company reported the revenue of 57.24 M. Net Loss for the year was (45.39 M) with profit before overhead, payroll, taxes, and interest of 33.35 M. | |
| Enzymatica publ AB has accumulated about 64.82 M in cash with (35.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 64.0% of the company shares are held by company insiders |
- Analyzing Enzymatica Publ's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enzymatica Publ's stock is overvalued or undervalued compared to its peers.
- Examining Enzymatica Publ's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enzymatica Publ's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enzymatica Publ's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enzymatica Publ's stock. These opinions can provide insight into Enzymatica Publ's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.